January 11, 2013
A Tennessee federal judge on Thursday tossed a shareholder class action against BioMimetic Therapeutics Inc. and its two top executives, ruling that the plaintiffs had failed to prove the orthopedics company lied about the progress of approval for a bone injury treatment that decimated its stock price.
July 07, 2011
A BioMimetic Therapeutics Inc. investor filed a securities class action Wednesday in Tennessee accusing the medical device maker of lying about the progress of approval for a new bone injury treatment, causing its stock price to plummet when a safety panel questioned the product's potential to cause cancer.